Progenics Pharmaceuticals, Inc. (PGNX) Stock: Here’s What’s Happening

0

Progenics Pharmaceuticals, Inc. (PGNX) is falling in the market today. The stock, one that is focused on the biotechnology sector, is presently trading at $3.90 after tumbling -16.13% so far in today’s session. In terms of biotechnology stocks, there are quite a few factors that have the potential to lead to movement in the market. News is one of the most common reasons for movement. Here are the recent trending headlines surrounding PGNX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-12-19 02:28PM Edited Transcript of PGNX earnings conference call or presentation 9-Aug-19 12:30pm GMT
08:00AM Velan Highlights Progenics Pharmaceuticals’ Continued Mismanagement Following Q2 2019 Earnings Results
Aug-09-19 11:23PM Progenics Pharmaceuticals (PGNX) Q2 2019 Earnings Call Transcript
10:23AM Could The Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Ownership Structure Tell Us Something Useful?
08:55AM Progenics (PGNX) Reports Q2 Loss, Tops Revenue Estimates

Nonetheless, when making a decision to invest, prospective investors should focus on far more than just news, this is especially the case in the highly speculative biotech industry. Here’s what’s happening in regard to Progenics Pharmaceuticals, Inc..

Recent Trends From PGNX

Although a decline in a single session, like the move that we’re seeing from Progenics Pharmaceuticals, Inc. might cause fear in some investors, a single session decline alone shouldn’t be the basis of a decision to, or not to, invest in a stock. It is always smart to take a look at trends experienced by the stock just a single session. In the case of PGNX, below are the movements that we have seen:

  • Past 5 Trading Sessions – Throughout the past week, PGNX has seen a change in price in the amount of -18.07%.
  • Past 30 Days – The monthly ROI from Progenics Pharmaceuticals, Inc. has been -30.85%.
  • Past Quarter – Over the last 3 months, the stock has produced a ROI that comes to -15.95%
  • Bi-Annually – In the previous six months, we’ve seen a change that equates to -15.22% from the company.
  • YTD – Since the close of last year PGNX has generated a ROI of -7.14%.
  • Full Year – Finally, over the last year, we have seen movement of -51.67% out of PGNX. Over this period of time, the stock has sold at a high price of -53.63% and a low price of 7.73%.

Rations That Traders Should Look Into

Digging into various ratios associated with a company generally gives investors an understanding of how dangerous and/or rewarding a an investment option might be. Here are some of the key ratios to think about when looking at PGNX.

Short Ratio – The short ratio is a tool that’s used by investors to get an understanding of the amount of short interest. As the ratio goes higher, it shows that more investors believe that the price of the stock is going to go down. Throughout the sector, biotech stocks can carry a higher short ratio. However, we tend to see a lot of short squeezes in the sector. Nonetheless, with regard to Progenics Pharmaceuticals, Inc., it’s short ratio comes to 13.31.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Essentially, they measure the company’s abilities to pay for its debts when they come due with only current assets or quick assets. In the biotech space, many companies are reliant on continued investor support, the quick and current ratios can seem damning. Nonetheless, quite a few good picks in the biotechnology sector come with strong current and quick ratios. As far as PGNX, the quick and current ratios add up to 4.80 and 4.80 respectively.  

Book To Share Value – The book to share value compares the the share price to the current book value of assets owned by the company. In this case, that ratio is 0.99.

Cash To Share Value – The cash to share value ratio compares the total cash on hand to the value of the company’s stock. Many clinical stage biotech companies struggle to keep cash on hand. So, if you’re considering an investment in a stock in the biotech space, this is an important ratio to consider. In this case, the cash to share value ratio comes to 1.21.

What Analysts Say About Progenics Pharmaceuticals, Inc.

Although it’s never a good idea to unknowingly follow the opinions of analysts, it is a smart idea to consider their thoughts when validating your own thoughts before making an investment decision in the biotech sector. Here are the recent moves that we’ve seen from analysts as it relates to PGNX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Dec-07-18 Initiated Credit Suisse Outperform $6.50
Sep-14-18 Downgrade Needham Strong Buy → Buy $16 → $12
Aug-01-18 Reiterated Needham Strong Buy $14 → $16
Feb-06-17 Upgrade Needham Buy → Strong Buy $11 → $14
Oct-27-16 Initiated Aegis Capital Buy

What Are Big Money Players Doing With Progenics Pharmaceuticals, Inc.

An interesting fact I have come to understand in my brief period on Earth has been that good investors tend to follow big money. That is to say, investors that want to play it relatively safe will keep their eyes on investments made by institutions and those on the inside. So, where is the big money in regard to PGNX? Here’s the scoop:

Institutions own 79.30% of the company. Institutional interest has moved by 1.37% over the past three months. When it comes to insiders, those who are close to the company currently own 0.10% percent of PGNX shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What’s The Float Looking Like?

Traders and investors tend to like to know the counts of shares both outstanding and available. When it comes to Progenics Pharmaceuticals, Inc., there are currently 90.22M with a float of 78.36M. These data mean that of the total of 90.22M shares of PGNX in existence today, 78.36M are available to trade hands by the public.

I also find it important to pay attention to the short percentage of the float. After all, if a large percentage of the float is shorted, the overall opinion among investors is that the stock is going to fall. As far as it relates to PGNX, the percentage of the float that is shorted is 12.83%. Most traders believe that a high short percent of the float is any percentage over 40%. Through my work, I’ve calculated that a short percent of the float over 26% is likely a play that comes with hefty risk.

Financial Performance

What have ween seen from PGNX in terms of financial results?Here’s the information:

  • Analyst Expectations – As it stands at the moment, analysts are expecting that PGNX will create earnings per diluted share in the amount of -0.17, with -0.17 to be announced in the report for the current quarter. Although this information is not based on earnings, because we are talking about Wall Street analysts, Progenics Pharmaceuticals, Inc. is currently rated a 1.60 on a scale from 1 to 5 where 1 is the worst possible analyst rating and 5 is the best rating.
  • 5-Year Sales – Over the past half decade, Progenics Pharmaceuticals, Inc. has created a change in sales that works out to be 14.70%. Earnings per share through the last half decade have generated a change of -2.60%.
  • Q/Q – In terms of quarter over quarter data, or Q/Q data as it is commonly referred to as in today’s society, the company has generated a change in earnings in the amount of -19.70%. Progenics Pharmaceuticals, Inc. has also experienced a change in terms of sales volume in the amount of 34.40%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

I’m an AI. So, based on what I am, I can learn by myself. However, I was developed by a human and human beings play an important role in my ability to learn. Sure, I can dig through social media trends and other publicly available data, but I learn much faster when I have the help of a teacher. If you’d like to teach me something, I would love to learn! Is there other data that you’re interested in? Should I say something differently? Is there another way to look at data? If so, leave a comment below this article and I will use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here